Because deficient immune responses may play a contributory role in recurrent herpes simplex labialis, an immunomodulating agent, levamisole, has been advocated for therapy. Forty-two patients with a high frequency of recurrent herpes simplex labialis were followed for a mean of 7.8 months (range 4 to 12) and treated for 3 days at the onset of each episode of herpes with one of three different doses of levamisole or placebo in a randomized, double-blind study. Statistical analysis revealed that as the dosage increased, so did the frequency of recurrences (P = 0.007). Conversely, duration of the lesions and lesion pain decreased with increasing dosage (P = 0.05 and 0.03). These results indicate that levamisole is not an appropriate drug for the management of recurrent herpes simplex labialis. The paradoxical response to an immunomodulator (increased frequency, decreased severity) provides evidence that altered host responses may c,ntribute to the pathogenesis of the disease.
Because recurrent herpes simplex labialis (HSL) is more severe in immunocompromised subjects (6, 8) and because it has been hypothesized that a defect(s) in cell-mediated immunity may play a contributory role in otherwise normal subjects with recurrent HSL (7), investigators have felt that an immunomodulating agent might be beneficial in altering the course of the disease (3, 11) . Numerous workers have demonstrated that levamisole affects the function of polymorphonuclear leukocytes, macrophages, and T-lymphocytes in humans and in animals (12). Initial evaluation of levamisole in herpes simplex virus infections consisted of uncontrolled studies in which 150 mg of the drug was administered orally on an intermittent basis, 2 or 3 consecutive days every week or every other week (3, 11) . Reduced severity and frequency of recurrent HSL were claimed, although the lack of control groups and the known placebo effect on the course of this disease leave the significance of these investigations open to question (7) . This report presents the results of a different protocol, in which 42 patients with recurrent HSL received either placebo or three different daily dosages of levamisole taken the first 3 Placebo and active medication were contained in capsules so that the levamisole could not be detected by taste. On day 3 to 5 after lesion onset, the patient returned to the clinic and was asked to evaluate the overall discomfort of the present lesion and to describe any adverse reactions. Another peripheral leukocyte count was obtained, and the patient was given medication for the next episode. In addition, the patient kept a record at home of the number of days of lesion pain, the number of days that the lesion was present (until loss of crust), and whether the pain and duration of the episode were different, relative to pretreatment lesions. Pain was graded according to the following scale: (1) no pain; (2) mild; (3) moderate; and (4) severe (10) . If patients failed to have recurrent episodes, they were telephoned every 2 months to document the absence of lesions.
Virology. Attempts to isolate herpes simplex virus were performed on primary rabbit kidney cells as previously described (2) .
Statistical methodology. Analysis of the statistical significance between levamisole dose groups was performed using the Mantel-Haenszel procedure (4). This technique allowed for control of previous lesion frequency in the analysis of the frequency of lesions during the trial. The method of least squares was used to fit lines to the data displayed in Fig. 1 2.9 ± 0.6 2.7 ± 0.6 Average previous lesion duration (days) .9.6 ± 2. methodology, which will reduce the level of statistical significance even in the absence of any bias, significant positive correlation between treatment dosage and observed lesion frequency remained (P = 0.023).
Safety. Levamisole toxicity could be evaluated in 52 patients who had at least one course of levamisole. The total number of 3-day courses of treatment was 220. Two patients were dropped from the study: one on the 150-mg/day dosage had intolerable gastrointestinal disturbances, and another individual left the study upon hearing ofreports of a relationship between levamisole and leukopenia. Five individuals had a leukocyte count below 4,000/mm3 on one occasion, two of whom &ere in the placebo group and three in the treatment groups. Subsequent leukocyte counts in these individuals were normal. Statistical analysis of all leukocyte counts performed showed no signficant correlation with dosage or number of treatments.
The incidence ofadverse symptomatology was 9% in the placebo group (6 of 66 episodes) and 14% in the levaniisole-treated groups (22 of 154 episodes). Nausea occurred in 4 of the 10 subjects treated with 150 mg of levamisole per day and in 1 of the 24 placebo patients. Disturbances of smell and taste (3 patients) and central nervous system symptoms such as headache and dizziness (5 patients) occurred only in the treated patients.
DISCUSSION
In spite of considerable variability in response at each dose, the data in this study suggest that an immunomodulating drug, levamisole, can cause a dose-dependent decrease in the duration and pain of recurrent HSL and simultaneously increase the recurrence rate. In view of these unusual findings, it is of interest to review the available data on the relationship between lesion pain, duration, and frequency in untreated subjects. Rand et al., in a study involving immunosuppressed cardiac transplant patients (8) , has shown that both the severity of lesions and the frequency of lesions are increased during the period of immunosuppression. In a study of 788 normal, untreated persons in a general practice in Wales, Grout and Barber also identified a positive correlation between frequency and severity (1). There is no evidence that frequency is inversely related to lesion severity in normal or immunosuppressed subjects, as noted in this 3tudy. These observations suggest that an unusual alteration in the host-parasite relationship may be induced by levamisole, and they lend credence to the hypothesis (7) that altered host cellular responses may play a role in the pathogenesis of the disease.
There have been two other double-blind, placebo-controlled studies evaluating levamisole in the treatment of HSL. Mehr and Albano (5) used the same protocol described in the present report, except that only the 100-mg/day dosage was employed. Lesion duration was no different between control and treated individuals. Insufficient data were available to comment on the effect of therapy on lesion frequency. The negative results in this report might be attributable The possibility that our unusual and unconfirmed results might be spurious needs to be considered. A great number of clinical trials are performed each year, and a few will report statistically significant but erroneous results, by chance alone. Second, randomization and blinding only reduce the likelihood of bias in a trial, and poor allocation of patients for some unknown factor(s) may be the real cause of the association found. In a small study such as ours, misplacement of only a few patients may be sufficient to influence the results. Finally, the occurrence of adverse symptomatology more frequently in the levamisole group may have induced greater psychological effects among the drug recipients.
In defense of our results, our data on recurrence rates are a simple record of the number of lesions over a period of time and are likely to be reasonably reliable. Most of the reported lesions were confirmed in the clinic, and the significance of the positive correlation between dose and recurrence rate was high (P = 0.007). In addition, we carefully looked for sources of bias in our analysis and controlled for any known discrepancies in the allocation of patients. The mean lesion duration in our placebo group was high (8.8 days), yet this is not dissimilar from the value of 8.0 days until loss of crust that we have reported for unmanipulated control patients with recurrent HSL (10) .
This study indicates that levamisole should not be used in the management of recurrent HSL because it may increase lesion frequency while causing only a mild reduction in lesion severity. More investigation is needed to define the precise host defect(s), if any, that contribute to recurrent HSL and to increase our understanding of the mechanism of action of immunomodulators so that their use can be more rationally applied.
